Rotavirus gastroenteritis is a major health problem among Malawian children. Studies spanning 20 years have described the importance, epidemiology and viral characteristics of rotavirus infections in the country. Despite a wide diversity of circulating rotavirus strains causing severe disease in young infants, a clinical trial of a human rotavirus vaccine clearly demonstrated the potential for ...

The present statement provides information concerning the clinical rotavirus disease and rotavirus vaccines in Canada. Since the implementation of publically funded rotavirus vaccine programs in Canada, increasing evidence has been accumulating globally as to the effectiveness of rotavirus vaccines in the prevention of acute gastroenteritis. Current data estimate vaccine effectiveness to be in ...

After the introduction of monovalent rotavirus vaccine (RV1) in Mexico in 2006-2007, diarrhea mortality and morbidity declined substantially among Mexican children under 5 years of age. In January 2010, surveillance identified the emergence of a novel G9P[4] rotavirus strain nationwide. We conducted a case-control study to assess the field effectiveness of RV1 against severe rotavirus gastroent...

INTRODUCTION Rotavirus remains the leading cause of severe diarrhea in children under 5 years worldwide. In the US, Rotarix (RV1) and RotaTeq (RV5), have been associated with reductions in and severity of rotavirus disease. Studies have evaluated the impact of RV1 or RV5 but little is known about the impact of incomplete or mixed vaccination upon vaccine effectiveness. METHODS Case control st...

Background & Aims: Diarrheal diseases are one of the major causes of morbidity and mortality in infants and toddlers in developing countries and Rotavirus is the single most important cause of severe infantile gastroenteritis worldwide. This study was conducted to estimate the frequency and clinical manifestations of rotavirus infection in children below 3 years old with acute gastroenteritis r...

Background: The rotavirus vaccine, introduced in 2006, has had a difficult history. Rotavirus accounts for 30% to 50% of hospitalizations for acute gastroenteritis and perhaps even more emergency department (ED) visits. Because rotavirus is not always tested for and detected, data are incomplete. Without knowing the actual burden of rotavirus, it is impossible to determine how the vaccination w...

The development and implementation of safe and effective vaccines to prevent the enormous health burden of rotavirus-associated disease is a global public health goal. Human rotaviruses, the major aetiological agents of severe infantile diarrhoea worldwide, display surprisingly diverse and complex serotypic specificities. Ten VP7 serotypes and 7 VP4 serotypes have so far been detected. An incre...

BACKGROUND Rotavirus illness has been linked to childhood seizures. We investigated whether a protective association exists between receipt of rotavirus vaccine and being hospitalized or visiting the emergency department for seizures in the year after vaccination. METHODS We retrospectively analyzed a cohort of children born after 28 February 2006 (when rotavirus vaccine was licensed in the U...

BACKGROUND Libya introduced rotavirus vaccine in October 2013. We examined pre-vaccine incidence of rotavirus hospitalizations and associated economic burden among children < 5 years in Libya to provide baseline data for future vaccine impact evaluations. METHODS Prospective, hospital-based active surveillance for rotavirus was conducted at three public hospitals in two cities during August 2...

As of January 2016, 80 countries have introduced rotavirus vaccines into their national immunization programs. Many have documented significant declines in rotavirus-specific and all-cause diarrheal illnesses following vaccine introduction. Two globally licensed rotavirus vaccines have been associated with a low risk of intussusception in several studies. In July 2014, the Rotavirus Organizatio...